Clinical impact of dyspnoea after ticagrelor treatment and the effect of switching to clopidogrel in patients with myocardial infarction.

Sang Hyun KimSanghoon ShinEun-Ho ChooIk Jun ChoiSungmin LimDonggyu MoonChan Joon KimMahn-Won ParkMin Chul KimByung-Hee HwangKwan Yong LeeYun-Seok ChoiHee-Yeol KimKi-Dong YooDoo Soo JeonYoungkeun AhnKiyuk Chang

Published in: Thrombosis and haemostasis (2024)

Dyspnoea is a common side effect among ticagrelor-based DAPT in AMI patients. Switching from ticagrelor to clopidogrel after 1 month in AMI patients may provide a reasonable option to alleviate subsequent dyspnoea in ticagrelor-relevant dyspnoeic patients, without increasing the risk of ischaemic events (NCT02018055).

Keyphrases

acute coronary syndrome
end stage renal disease
percutaneous coronary intervention
antiplatelet therapy
ejection fraction
chronic kidney disease
prognostic factors
acute myocardial infarction
st segment elevation myocardial infarction
coronary artery disease
atrial fibrillation